PROCEPT BioRobotics Corporation
PRCTNASDAQHealthcare● Active
$28.35
+$0.52(+1.87%)
Market Cap$1.6B
P/E Ratio—
52W High$64.92
52W Low$19.35
PROCEPT BioRobotics Corporation (PRCT) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · PRCT · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | ($0.10B) | ($0.09B) | ($0.11B) | ($0.09B) | ($0.06B) |
| Depreciation & Amort. | $0.01B | $0.01B | $0.00B | $0.00B | $0.00B |
| Stock-Based Comp. | $0.05B | $0.03B | $0.02B | $0.01B | $0.00B |
| Change in Working Capital | ($0.01B) | ($0.05B) | ($0.03B) | ($0.01B) | ($0.00B) |
| Net Cash from Operations | ($0.05B) | ($0.10B) | ($0.11B) | ($0.08B) | ($0.06B) |
| Investing Activities | |||||
| Capital Expenditure | ($0.01B) | ($0.00B) | ($0.03B) | ($0.00B) | ($0.00B) |
| Purchases of Investments | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Sales of Investments | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Cash from Investing | ($0.01B) | ($0.00B) | ($0.03B) | ($0.00B) | ($0.00B) |
| Financing Activities | |||||
| Common Stock Repurchased | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Dividends Paid | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Debt Issued / Repaid | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Cash from Financing | $0.01B | $0.18B | $0.17B | $0.00B | $0.26B |
| Free Cash Flow | |||||
| Free Cash Flow | ($0.06B) | ($0.10B) | ($0.13B) | ($0.08B) | ($0.06B) |
| FCF Margin %(computed) | -18.94% | -46.16% | -97.81% | -110.69% | -168.03% |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · USD · B
Explore more PROCEPT BioRobotics Corporation data
About PROCEPT BioRobotics Corporation (PRCT) Cash Flow Statement
PROCEPT BioRobotics Corporation generated operating cash flow of ($0.05B) and free cash flow of ($0.06B) for 2025 — a FCF margin of -18.94%. Capital expenditure was ($0.01B).
Frequently asked questions
PRCT · 4 questionsPROCEPT BioRobotics Corporation generated free cash flow of ($0.06B) for 2025, up 43.7% year-over-year.
PRCT free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10